KALA BIO, Inc. (KALA) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $3.14 (+18.94%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
Top Analysts Covering KALA
KALA vs Sector & Market
| Metric | KALA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.40 |
| Analyst Count | — | 8 | 19 |
| Target Upside | +615.7% | +11474.3% | +17.1% |
| P/E Ratio | -0.03 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $25M | $25M | $25M | 1 |
| 2027-12-31 | $26M | $26M | $26M | 1 |
| 2028-12-31 | $134M | $134M | $134M | 1 |
| 2029-12-31 | $229M | $229M | $229M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.53 | $-0.53 | $-0.53 | 1 |
| 2027-12-31 | $-0.40 | $-0.40 | $-0.40 | 1 |
| 2028-12-31 | $-0.18 | $-0.18 | $-0.18 | 1 |
| 2029-12-31 | $-0.17 | $-0.17 | $-0.17 | 1 |
Frequently Asked Questions
What is the analyst consensus for KALA?
The consensus among 0 analysts covering KALA BIO, Inc. (KALA) is — with an average price target of $18.25.
What is the highest price target for KALA?
The highest price target for KALA is $10.50, set by Yi Chen at H.C. Wainwright on 2024-04-03.
What is the lowest price target for KALA?
The lowest price target for KALA is $7.50, set by Yi Chen at H.C. Wainwright on 2024-08-07.
How many analysts cover KALA?
0 analysts have issued ratings for KALA BIO, Inc. in the past 12 months.
Is KALA a buy or sell right now?
Based on 0 analyst ratings, KALA has a consensus rating of — with a +615.7% upside to the consensus target of $18.25.
What are the earnings estimates for KALA?
Analysts estimate KALA will report EPS of $-0.53 for the period ending 2026-12-31, with revenue estimated at $25M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.